Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib
- Authors
- Lee, Jae Hoon; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang Hyub; Seo, Hyo Jung; Lee, Jong Doo; Choi, Hye Jin
- Issue Date
- Sep-2011
- Publisher
- WILEY-BLACKWELL
- Keywords
- 18F-FDG PET; hepatocellular carcinoma; sorafenib
- Citation
- LIVER INTERNATIONAL, v.31, no.8, pp 1144 - 1149
- Pages
- 6
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- LIVER INTERNATIONAL
- Volume
- 31
- Number
- 8
- Start Page
- 1144
- End Page
- 1149
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/35177
- DOI
- 10.1111/j.1478-3231.2011.02541.x
- ISSN
- 1478-3223
1478-3231
- Abstract
- Background: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used 18F-2-fluoro-2-deoxyglucose (18F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC.
Materials and methods: A total of 29 patients with HCC were included. Baseline 18F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400 mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient.
Results: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0–12.0] and 3.8 months (95% CI: 1.4–6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively).
Conclusion: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 5. Others > Others(Medicine) > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.